Abstract
Introduction

Nanobiotechnology is the assembling of biological molecules into 1 to 100 nanometer dimensions. These dimensions can be the diameter of nanodimension artificial cells or particles; membranes with nanodimension thickness or nanotubules with nanodimension diameter. The first nanobiotechnological approach reported in the literature is the crosslinking of Hb into ultrathin polyHb (PolyHb) membrane for
artificial red blood cell membrane [1, 2] [3] . New [4] [5] [6] 
. If the emulsion is made even smaller, then the whole artificial cells with its Hb can be crosslinked into PolyHb of nanodimension. Glutaraldehyde can crosslink Hb into soluble PolyHb of nanodimension
generations of this approach includes the nanobiotechnological assembly of hemoglobin, catalase and superoxide dismutase into a soluble nanodimension complex. This acts both as oxygen carrier and antioxidant for those conditions with potentials for ischemia-reperfusion injuries (4-7). Another recent novel approach is the assembling of hemoglobin and fibrinogen into a soluble nanodimension polyhemoglobin-fibrinogen complex that act as an oxygen carrier with platelet-like activity (6). This is potentially useful in cases of extensive blood loss requiring massive replacement using blood substitutes resulting in the need for platelet and clotting factors replacement. Nanodimension artificial cells can also be formed in the form nanodimension biodegradable polymeric membrane artificial cells containing Hb and rbc enzymes
Polyhemoglogin
Basic principles Hb is a tetramer (α1β1α2β2) (8)that breaks down into toxic dimers (α1β1 and α2β2)
that cause renal toxicity and other adverse effects. Even in the form of tetramers, Hb molecules can cross the intercellular junction of blood vessels to cause adverse vasopressor effects. We have used the principle of nanobiotechnology to assemble Hb molecules into nanodimenion polyHb first using bifunctional agent sebacyl chloride [1] [2] , then glutaraldehyde [3] . The glutaraldehyde method has been developed independently by other groups for clinical trials (9, 10) 
The changes in brain water content of PolyHb-SOD-CAT treated animals are not significantly different from that of the sham control. The increase in water contents of saline, SF-Hb, SF-Hb + SOD + CAT, and PolyHb are significantly different from that of the sham control and PolyHb-SOD-CAT group by the 4th h continued to increase and thereon with time. Statistical significance is P < 0.01. (copyright permission from 2007 monograph on Artificial Cells [4]) Figure 3. In obstructive ischemia polyhemoglobin supplies oxygen but may cause ischemia-reperfusion injuries. On the otherhand, polyHb-SOD-CAT can supply oxygen without causing ischemia-reperfusion injuries. (copyright permission from 2007 monograph on Artificial Cells [4])
Polyhemoglobin-Fibrinogen: a Novel Oxygen Carrier With Platelet-like Properties
In high blood volume loss, large volume red blood cell replacement alone would not replace platelets and coagulation factors and there is need to replace these also. We therefore use nanobiotechnology to develop a blood substitute that is an oxygen carrier with platelet-like properties. This is a novel blood substitute, polyhemoglobinfibrinogen (polyHb-Fg) [16]. Briefly, PolyHb-Fg was prepared as follows. A fibrinogen solution of 40mg dissolved in 4 mL of Ringer's lactate was added 4 hours after polymerization began. After 24 hours of polymerization, the reaction was stopped by quenching with 2.0M lysine solution in a molar ratio of 200:1 lys to Hb. The solutions were then dialyzed against a Ringer's lactate solution overnight.
In vitro experiments
In vivo experiments
The results are shown in Figure 4 . Figure 5 ) [18] [19] [20] [21] . Polylactide is degraded in the body into lactic acid and then water and carbon dioxide. For a 500 ml suspension, the total lactic acid produced is 83 mEq [5] . This is far less than the normal resting-body lactic acid production (1000-1400 mEq/day). This is equivalent to 1% of the capacity of the body to breakdown lactic acid (7080 mEq/day).
Figure 5. Nano artificial red blood cells with diameters of 80-100 nanometers containing hemoglobin and red blood cell enzymes (Copyright permission from 2007 monograph on Artificial Cells [4])
In vitro studies Bovine hemoglobin in these nano dimension artificial red blood cells has the same P 50 , Bohr and Hill coefficients [4] [5] [6] . The content of hemoglobin can match that of red blood cells [4] [5] [6] [18, 22] . Furthermore, reducing agents from the plasma can diffuse into the nanocapsules to reduce methemoglobin to oxygen carrying hemoglobin. [18, 22] In vivo studies Rats have been infused with 1/3 the total blood volume. Most recently, we use a composite biodegradable polymeric membrane consisting of co-polymer of polyethylene glycol (PEG) with polylactic acid (PLA) [22] . After extensive research using this approach, we have now prepared nano-dimension artificial red blood cells that can retain their circulating hemoglobin level at double the duration of polyhemoglobin [22] . We investigate the long term effects of PEG-PLA nano artificial cells containing hemoglobin (NanoRBC) on renal and liver function and also renal, liver and spleen histology after 1/3 blood volume top loading in rats [24, 25] [26, 27] . This has the combined function of increasing oxygen tension to sensitize the melanoma to therapy and lowering systemic tyrosine to retard the growth of a fatal skin cancer, melanoma. Many other extensions and modifications of this general principle in nanobiotechnology are possible (27) . (28, 29) . The transfusion of stored packed rbc is also associated with an increase in ischemic coronary events (28, 30 
GENERAL DISCUSSIONS
